Document is current
Any future updates will be listed below
-
Authors
Luo, Linjie
Yang, Peng
Mastoraki, Sofia
Rao, Xiayu
Wang, Yan
Kettner, Nicole M.
Raghavendra, Akshara Singareeka
Tripathy, Debasish
Damodaran, Senthil
Hunt, Kelly K.
Wang, Jing
Li, Ziyi
Keyomarsi, Khandan
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 2 January 2025
First Online: 15 February 2025
Declarations
:
: Tumor biopsy samples were collected from patients with HR+/HER2- mBC treated at the University of Texas MD Anderson Cancer Center under the Institutional Review Board (IRB)-approved protocol (PA19-0047). All participants signed informed consent. Clinical data were sourced from electronic medical records (OneConnect and Care Everywhere) and a prospectively maintained Breast Cancer Management System, managed by the Breast Medical Oncology Department from the University of Texas MD Anderson Cancer Center.The validation cohort comprised published sequencing data from Korean patients with HR+/HER2- mBC (NCT03401359) []. This cohort included patients with recurrent and/or mBC treated with palbociclib plus endocrine therapy at Samsung Medical Center and Seoul National University Hospital from 2017 to 2020. All participants signed informed consent. Patients who refused to provide informed consent or withdrew from the study were excluded.
: K.K.: Apeiron, Blueprint Medicines, REPARE, Schrodinger, and Novartis. K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. S.D.: EMD Serono, Guardant Health, Novartis, Pfizer, Sermonix, Taiho. D.T.: AstraZeneca, GlaxoSmithKline, Gilead, Novartis, OncoPep, Pfizer, Polyphor, Personalis, Puma Biotechnology, Sermonix, Stemline-Menarini. The rest of the authors declare no competing interests.
